Q3 figures stall even though Pfizer’s trying to provide a vaccine for the world
Despite its efforts to be one of the frontrunners in the
race of finding a COVID-19 vaccine, Pfizer didn’t have a good quarter.
In Q3, Pfizer
reported revenues of $12.13 billion, below the $12.31 billion consensus. The
EPS was of $0.72, higher than the $0.69 expected.
But the quarterly earnings weren’t the only news from
Pfizer. The company stated that it is currently unable to release data about
the potential CVOID-19 drug that they’re developing alongside BioNTech. The
reluctance comes because the independent monitor that’s reviewing the data
hasn’t conducted an extended analysis to determine if the vaccine is viable or
not.
Following the news, Pfizer stock price lost more than 1%.
Year-to-date, the company’s stock price went down roughly 3%.
Sources: finance.yahoo.com, investing.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Ant Group about to make history in blockbuster IPO
Next Article
There’s no wind under Boeing’s wings
